Trial Profile
A Phase II Randomized Study to Evaluate the Immunologic and Antitumor Activity of Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Advanced HER2-overexpressing Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs AVX 901 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Pharmacodynamics
- 17 May 2023 Status changed from recruiting to active, no longer recruiting.
- 19 Dec 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 19 Dec 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.